APP, in conjunction with the FDA, began importing Fresenius Propoven 1% in late 2009 but stopped in Feb. 2010 when the initial supply ran out, according to the letter.
Effective immediate, APP, which is the only company authorized to import Fresenius Propoven 1%, will begin importing the following products:
- DIPRIVAN (20-mL, 50-MI and 100-mL vials)
- APP Propofol 1% (20-mL, 50-MI and 100-mL vials)
- Fresenius Propoven 1% (20-mL, 50-MI and 100-mL vials)
The letter also notes some important difference between U.S.-manufactured propofol and international Fresenius Propoven 1%, including contraindication in patients with peanut and soy allergies. For complete information on the difference, please refer to the APP’s letter.
Read APP’s letter on Fresenius Propoven 1% (pdf).
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
